Technology

NeuBase Therapeutics

$10.08
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.43 (+16.53%) Today
$0.00 (0.00%) As of 10:22 AM UTC after-hours

Why Robinhood?

You can buy or sell NBSE and other stocks, options, and ETFs commission-free!

About NBSE

NeuBase Therapeutics, Inc. Common Stock, also called NeuBase Therapeutics, is a biotechnology company. It engages in the development of drugs for patients with genetic neurological disorder. The firms pipelines include Huntington’s Disease, NT0100 Program - PATrOL Enabled gamma-PNA for Huntington's Disease, and NT0200 Program- PATrOL Enabled gamma-PNA for Myotonic Dystophy. The company was founded by Dietrich A. Stephan on August 28, 2018 and is headquartered in Pittsburgh, PA. The listed name for NBSE is NeuBase Therapeutics, Inc. Common Stock.

CEO
Dietrich A. Stephan
Employees
15
Headquarters
Pittsburgh, Pennsylvania
Founded
2018
Market Cap
191.77M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
553.46K
High Today
$10.45
Low Today
$8.82
Open Price
$9.22
Volume
1.80M
52 Week High
$11.78
52 Week Low
$4.52

Collections

NBSE Earnings

-$0.40
-$0.27
-$0.13
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Mar 25, After Hours

You May Also Like

TEO
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure